These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 7528134)

  • 1. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.
    Friedel HA; Balfour JA
    Drugs; 1994 Oct; 48(4):638-60. PubMed ID: 7528134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
    Cheer SM; Dunn CJ; Foster R
    Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.
    Hoy SM; Scott LJ; Plosker GL
    Drugs; 2010 Jul; 70(10):1319-47. PubMed ID: 20568836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.
    Barradell LB; Buckley MM
    Drugs; 1992 Nov; 44(5):858-88. PubMed ID: 1280570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Davis R; Faulds D
    Drugs Aging; 1997 Apr; 10(4):299-322. PubMed ID: 9108990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tinzaparin sodium: a low-molecular-weight heparin.
    Neely JL; Carlson SS; Lenhart SE
    Am J Health Syst Pharm; 2002 Aug; 59(15):1426-36. PubMed ID: 12166042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
    Cziraky MJ; Spinler SA
    Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tinzaparin in the treatment of venous thromboembolism.
    Pineo GF; Hull RD
    Expert Opin Pharmacother; 2003 Dec; 4(12):2355-62. PubMed ID: 14640933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
    Wellington K; McClellan K; Jarvis B
    Drugs; 2001; 61(8):1185-209. PubMed ID: 11465877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
    Hyers TM; Spyropoulos AC;
    J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.
    Frampton JE; Faulds D
    Drugs; 1994 Apr; 47(4):652-76. PubMed ID: 7516862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.
    Noble S; Peters DH; Goa KL
    Drugs; 1995 Mar; 49(3):388-410. PubMed ID: 7774513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
    Bara L; Planes A; Samama MM
    Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Den Belt AG; Prins MH; Lensing AW; Castro AA; Clark OA; Atallah AN; Burihan E
    Cochrane Database Syst Rev; 2000; (2):CD001100. PubMed ID: 10796593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
    Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
    Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
    Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
    Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical potential of low molecular weight heparins.
    Levine MN; Hirsh J
    Baillieres Clin Haematol; 1990 Jul; 3(3):545-54. PubMed ID: 2176904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty.
    Lassen MR; Borris LC; Jensen HP; Poulsen KA; Ejstrud P; Andersen BS
    Clin Appl Thromb Hemost; 2000 Jan; 6(1):53-7. PubMed ID: 10726050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Dunn CJ; Sorkin EM
    Drugs; 1996 Aug; 52(2):276-305. PubMed ID: 8841743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.
    Buckley MM; Sorkin EM
    Drugs; 1992 Sep; 44(3):465-97. PubMed ID: 1382939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.